Proposed Risk Stratification and Patterns of Radioactive Iodine Therapy in Malignant Struma Ovarii.

Overview

abstract

INTRODUCTION: Malignant struma ovarii (MSO) is a rare thyroid cancer arising within an ovarian teratoma. While surgical excision of the primary tumor is widely accepted as standard of care, recommendations for adjuvant treatment of MSO - whether or not to administer radioactive iodine (RAI)- is based largely on case reports and remains debated. Here we aimed to propose a risk stratification and analyze RAI utilization patterns in MSO cases. METHODS: The National Cancer Database (NCBD) was queried for patients with MSO between 2004 and 2016. Demographic, oncologic, and clinicopathologic data were compared between groups using Fisher's exact test. Kaplan-Meier curves were used to estimate overall survival (OS), and variables associated with OS were assessed via Cox univariate regression. We adapted the 2015 American Thyroid Association risk guidelines for MSO patients. We stratified patients into low-, intermediate- and high-risk groups using metastasis, extraovarian extension (EOE), lymphovascular invasion, lymph node status, surgical margins, tumor size, and grade. Risk stratification, demographic, oncologic, and clinicopathologic data were compared between groups receiving and not receiving RAI therapy. We then queried the Surveillance, Epidemiology and End Results (SEER) 18 registry for patients with MSO between 2000-2018 to confirm our risk-stratification analysis. RESULTS: In the NCDB analysis, a total of 158 patients were identified, and 19 received RAI. RAI therapy was associated with distant metastasis (p=0.005) and lymph node status (p=0.012). Twenty-one NCDB patients were stratified as high-risk, and 30% of high-risk patients received RAI. High-risk stratification was associated with decreased OS via univariate Cox regression (HR 4.0 [95%-CI 1.11-14.26], p=0.034). In our subsequent analysis using the SEER registry, there were 95 MSO patients, and 18 received RAI. Again, the majority of high-risk patients did not receive RAI, with only 41% of high-risk patients receiving RAI. CONCLUSIONS: MSO is a rare malignancy with apparently variable and inconsistent patterns of postoperative RAI administration. The risk stratification described here provides a framework to identify patients potentially at risk for mortality and utilization of RAI in this group should be studied further.